Induction Therapy with reduction of Calcineurin inhibitors
Showing 1 - 25 of >10,000
Renal Transplant Trial in Toledo (Arm 1 Everolimus/Reduced dose tacrolimus)
Completed
- Renal Transplant
- Arm 1 Everolimus/Reduced dose tacrolimus
-
Toledo, OhioUniversity of Toledo, Health Science Campus
May 2, 2022
Renal Insufficiency, Kidney Transplantation Trial in Amsterdam, Groningen, Leiden (tacrolimus OD, mycophenolic acid,
Completed
- Renal Insufficiency
- Kidney Transplantation
- tacrolimus OD, mycophenolic acid, prednisolone
-
Amsterdam, Netherlands
- +2 more
Dec 20, 2021
Chemo, Radiation Therapy Trial in Fuzhou (Camrelizumab, Paclitaxel, Cisplatin)
Not yet recruiting
- Chemotherapy
- Radiation Therapy
- Camrelizumab
- +3 more
-
Fuzhou, ChinaFujian Medical University Union Hospital
Apr 6, 2023
Aortic Valve Stenosis Trial in Seoul (Angiotensin Receptor-Neprilysin Inhibitor, antihypertensive drugs including RAS inhibitors
Not yet recruiting
- Aortic Valve Stenosis
- Angiotensin Receptor-Neprilysin Inhibitor
- antihypertensive drugs including RAS inhibitors (ACE inhibitors or ARB)
-
Seoul, Korea, Republic ofAsan Medical Center
Jan 4, 2023
Non-hodgkin Lymphoma, Hodgkin Lymphoma Trial in Valhalla (DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B)
Recruiting
- Non-hodgkin Lymphoma
- Hodgkin Lymphoma
- DOC Group B
- +16 more
-
Valhalla, New YorkNew York Medical College
Jun 9, 2022
Melanoma Trial in France (Nivolumab + Ipilimumab, Combined treatment schema)
Terminated
- Melanoma
- Nivolumab + Ipilimumab
- Combined treatment schema
-
Bordeaux, France
- +5 more
Dec 3, 2020
History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection Trial in Paris (1: discontinuation of
Terminated
- History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection
- 1: discontinuation of RAS blocker therapy
- 2: continuation of RAS blocker therapy
-
Paris, FranceCardiologie, Groupe Hospitalier Pitié-Salpêtrière
Apr 8, 2021
Acute Lymphoblastic Leukemia (ALL) in Partial Remission, Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid
Recruiting
- Acute Lymphoblastic Leukemia (ALL) in Partial Remission
- +2 more
- Cyclophosphamide 50mg
- Methotrexate
-
Riyadh, Saudi ArabiaKing Faisal Specialist Hospital & Research Center
Apr 4, 2022
Renal Transplantation; Complication Trial in Alexandria (serum magnesium level, FEMg)
Not yet recruiting
- Renal Transplantation; Complication
- serum magnesium level, FEMg
-
Alexandria, EgyptFaculty of Medicine, Aexandria University
Apr 25, 2022
NSCLC, Immunotherapy Trial in Ann Arbor (Dexamthasone)
Terminated
- Non-Small Cell Lung Cancer
- Immunotherapy
-
Ann Arbor, MichiganVA Ann Arbor Healthcare System, Ann Arbor, MI
Jan 6, 2023
Kidney Transplantation Trial in United Kingdom (Alemtuzumab, Basiliximab, Sirolimus)
Completed
- Kidney Transplantation
- Alemtuzumab
- +3 more
-
Oxford, Oxon, United Kingdom
- +19 more
Mar 23, 2020
Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life Trial in Worldwide (CDK 4/6 inhibitors, Endocrine therapy)
Not yet recruiting
- Metastatic Breast Cancer
- +4 more
- CDK 4/6 inhibitors
- Endocrine therapy
-
Helsinki, Finland
- +11 more
Sep 19, 2023
Lung Transplant; Complications Trial in Nashville (Tacrolimus Extended Release Oral Tablet [Envarsus], Tacrolimus, Mycophenolate
Not yet recruiting
- Lung Transplant; Complications
- Tacrolimus Extended Release Oral Tablet [Envarsus]
- +4 more
-
Nashville, TennesseeVanderbilt University Medical Center
Jun 6, 2022
SGLT-2 Inhibitors in the Treatment of Ascites
Recruiting
- Ascites Hepatic
- +2 more
- SGLT2 inhibitor
-
Palermo, Italy
- +1 more
Aug 11, 2023
NSCLC Stage III Trial (radiotherapy, Platinum-Based Drug, Immunotherapy)
Not yet recruiting
- Non-small Cell Lung Cancer Stage III
- radiotherapy
- +3 more
- (no location specified)
Sep 10, 2023
Renal Transplantation Trial in United States (Alemtuzumab, rabbit antithymocyte globulin, Belatacept)
Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia Trial (GVHD prevention: post-transplantation
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +5 more
- GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
- (no location specified)
Aug 23, 2022
Kidney Transplantation, Cytomegalovirus Infections Trial in L'Hospitalet de Llobregat (Switch from Mycophenolate Mofetil to
Not yet recruiting
- Kidney Transplantation
- Cytomegalovirus Infections
- Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm
- no intervention
-
L'Hospitalet de Llobregat, Barcelona, SpainHospital Universitari de Bellvitge
Jun 16, 2021
Acute Myeloid Leukemia Trial in Nanjing (Venclexta 100 MG Oral Tablet)
Recruiting
- Acute Myeloid Leukemia
- Venclexta 100 MG Oral Tablet
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Jun 11, 2023
Renal Allograft Recipients Trial in Worldwide (Belatacept, Tacrolimus, Cyclosporine A)
Recruiting
- Renal Allograft Recipients
- Belatacept
- +5 more
-
Birmingham, Alabama
- +14 more
Oct 24, 2022
Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)
Recruiting
- Nasopharyngeal Carcinoma
- Anti-EGFR and PD-1 inhibitor arm
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Sarcopenic Obesity in Liver Transplanted Patients
Recruiting
- Sarcopenic Obesity
- Evaluation of appendicular skeletal muscle mass (ASMM) by bioelectrical impedance analysis (BIA)
-
Bari, BA, Italy
- +1 more
Dec 26, 2021
Head and Neck Squamous Cell Carcinoma Trial in Guangzhou (Nab paclitaxel, Carboplatin, adelbelimumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Nab paclitaxel
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital
Aug 24, 2023
Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,
Not yet recruiting
- Muscle-Invasive Bladder Carcinoma
- +2 more
- Toripalimab
- +4 more
-
Guangzhou, Guangdong, ChinaCancer Center, Sun Yat-sen University
Aug 3, 2023